Enwei Pharmaceutical Co

Enwei Pharmaceutical Co Interest Coverage

The Interest Coverage Ratio of Enwei Pharmaceutical Co (301331.SZ) as of Oct 21, 2026 is 10.17. In the previous year, Interest Coverage Ratio was 8.96 — a change of 13.58% (higher).

Interest Coverage

10.17

YoY

13.58%

Last updated:

Interest Coverage Ratio of Enwei Pharmaceutical Co is 2024 10.17 . Interest Coverage Ratio of Enwei Pharmaceutical Co was 2023 8.96 . It decreases by 13.58% higher compared to the previous year.

The Enwei Pharmaceutical Co Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2019
82.51 CNY
Jan 1, 2020
110.68 CNY
Jan 1, 2021
144.26 CNY
Jan 1, 2022
44.34 CNY
Jan 1, 2023
8.96 CNY
Jan 1, 2024
10.17 CNY
The Enwei Pharmaceutical Co Interest Coverage history
YEARInterest CoverageYoY
10.17+13.58%
8.96-79.80%
44.34-69.26%
144.26+30.34%
110.68+34.15%
82.51—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Enwei Pharmaceutical Co Stock analysis

What does Enwei Pharmaceutical Co do? Enwei Pharmaceutical Co., Ltd. generates revenue through the research, development, production, and sales of proprietary Chinese and chemical medicines. The company's main products include Jieeryin lotion, Jieeryin ointment, Jieeryin effervescent tablets, Shanmai Jianpi oral liquid, Qingjing capsules, and Danxiong Tongmai granules, which are primarily sold via direct sales and e-commerce channels. Its focus on gynecological products, pediatric medicines, and respiratory medicines targets domestic consumers seeking specialized healthcare solutions. The firm's domestic market strategy emphasizes direct customer engagement and online sales to reach its target segments. The company's product portfolio is tailored to specific health needs, with Jieeryin products addressing gynecological concerns, Shanmai Jianpi oral liquid supporting digestive health, Qingjing capsules for gynecological treatments, and Danxiong Tongmai granules targeting cardiovascular health. These offerings are distributed through direct sales teams and e-commerce platforms, aligning with the domestic market's preference for accessible healthcare products. Enwei's domestic focus ensures that its products meet local regulatory standards and consumer demands. Enwei Pharmaceutical's revenue streams are driven by the consistent demand for its specialized medicine categories, particularly in gynecology, pediatrics, and respiratory care. The firm's domestic market presence allows it to build strong relationships with healthcare providers and end-users, facilitating repeat purchases and brand loyalty. By concentrating on these key therapeutic areas, Enwei effectively serves its core customer segments without expanding into international markets. Enwei Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enwei Pharmaceutical Co stock

Interest Coverage Ratio of Enwei Pharmaceutical Co is 10.17 in 2024.

Interest Coverage Ratio of Enwei Pharmaceutical Co changed from 8.96 to 10.17, representing a 13.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Enwei Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Enwei Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Enwei Pharmaceutical Co

All Key Metrics — Enwei Pharmaceutical Co